ClinicalTrials.gg
RecruitingNCT07599930SWAPUpdated May 20, 2026

Impact of a Novel Functional Snack on Perimenopausal Symptoms and Well-being

An interventional study of Functional Snacks and Placebo Snacks in Perimenopause, Perimenopause-Related Depression and Mood, sponsored by King's College London. Recruiting at 1 site in United Kingdom. Open to female participants aged 40 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by King's College London · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
40 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Depression by King's College London — 5 open to participants now, 8 under way, none of them phase 3. Depression · King's College London.

Planned enrollment
22nd of 25
20 · median 50
Started
2026
the only one that year
No phase
22 of 32
2 open now
Registered
31st of 32
by date

Among the 32 studies in Depression by King's College London, this one is the 22nd largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2026, is one of 22 with no phase, and was the 31st registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

5 of the 32 studies in Depression by King's College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 40 Years to 55 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Depression by King's College London, or all of them as a file.
02

Study summary

This is a clinical trial aimed to investigate if a novel phytochemical and fibre-rich snack can improve perimenopausal symptoms and well-being in perimenopausal women aged 40-55 and not on hormone replacement therapy.

Hypothesis: The investigators hypothesise that the phytochemical and fibre-rich snack will improve perimenopausal symptoms via a gut microbiota mediated mechanism.

Main research questions:

Does eating the snack every day lower menopause symptoms such as hot flushes, night sweats, mood changes, and sleep problems? Does the snack improve mood, stress, anxiety, sleep, and overall quality of life? Does the snack improve the balance of bacteria in the gut, and could this be part of how it helps symptoms?

Read the detailed description

This double-blind, randomised, placebo-controlled crossover trial will assess the effects of daily consumption for 4 weeks of a novel phytochemical- and fibre-rich granola snack created by TulaCode on menopausal symptoms. The effects of the snack will be compared to a calorie-matched placebo snack: a commercially available oat bar low in fibre and polyphenols. The study will also examine the impact of the intervention snack on mood, stress, sleep quality, cognition, depression and anxiety. Participants will be randomly assigned to either the intervention or the placebo snack for 4 weeks followed by a 4-week washout period before crossing over to the alternate snack for another 4 week period. Snacks will be consumed twice daily, and participants will be instructed to maintain their usual diet and physical activity while avoiding additional probiotic, prebiotic, or polyphenol-rich supplements throughout the study.

Participants will attend 4 in-person study visits at King's College London. At baseline, after 4 weeks, after 8 weeks (washout period) and after 12 weeks. Each study visit will take approximately 1 hour. On the day before each study visit, participants will be asked to self-collect their saliva, 24-h urine and stool samples at home, as well as finish a set of online questionnaires, and be fasted for 12 hours prior to their study visit.

Self-collection procedure of participants at home one day before study visits:

  1. Collect a total of 6 saliva samples throughout the day to measure cortisol levels and fill the saliva collection booklet.
  2. Collect a 24 h urine sample, starting in the morning after the first void urine, and finishing the next day collecting the first urine of the day (morning of the study visit day).
  3. Collect a small stool sample throughout the day for gut microbiome analysis.
  4. Fill the below online questionnaires:

    1. Positive and Negative Affect Schedule (PANAS-SF) questionnaire
    2. Hospital Anxiety and Depression Scale (HADS)
    3. Menopause Rating Scale (MRS)
    4. Cognitive Failure Questionnaire (CFQ)
    5. Perceived Stress Scale (PSS)
    6. World Health Organisation Quality of Life assessment instrument (EF-WHOQOL-100)
  5. Weekly questionnaire, 4 questionnaires per visit:

    1. International Physical Activity Questionnaire (IPAQ)
    2. Pittsburgh Sleep Quality Index (PSQI)
    3. Online 24 h dietary recall (Intake 24)
    4. 24h picture log of meals (OPIS)
    5. Gastrointestinal Symptom Rating Scale (GSRS)
    6. Menopause Rating Scale (MRS)
  6. Fill the below paper questionnaires:

    1. Food-Frequency Questionnaire - EPIC (only for visit 2)
    2. Food-Frequency Questionnaire - KCL polyphenol (only for visit 4)

On the morning of each study visit day, participants will bring their self-collected saliva, urine, and stool samples. Any Adverse events will be discussed and recorded. Any concomitant medication will be checked by the researchers that may impact on the eligibility criteria and the early completion of the study. Self-collected samples and completed online questionnaires will be checked. Blood pressure, heart rate and anthropometric measurements will be performed, waist-hip circumference will be measured, and fasting blood samples will be collected.

On Visit 1 (baseline), either intervention snack or a calorie-matched placebo snack will be provided to participants, with the amount should be enough for the 4-week study period. On Visit 3 (after 8 weeks), the crossover snacks will be provided to participants.

At the end of visit 1, 2 and 3, new self-collection kits and a link of online questionnaires will be distributed to participants to be used for next study visit.

03

Conditions studied

  • Perimenopause
  • Perimenopause-Related Depression
  • Mood
  • Sleep
  • Quality of Life
  • Gut -Microbiota

Browse trials for

Keywords

  • phytochemical
  • fibre
  • mood
  • sleep
  • quality of life
  • gut
04

Who can participate

Ages eligible
40 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 40 to 55
  • Score 14 or higher on the Menopause Rating Scale
  • For intervention purposes, eligible participants are also required to have a mobile phone and be able to read and speak English.

Exclusion criteria

Exclusion Criteria:

  • People who consume more than 15g of fibre a day
  • People who consume more than 2 cups of coffee or tea a day
  • People who consume more than 4 portions (portion = 80g) of fruits and vegetables a day
  • People who do not have any intolerances or allergies to the following:
  • Any kinds of nuts including tree nuts, peanuts, hazelnuts and coconuts
  • Chia seeds
  • Pumpkin seeds
  • Sunflower seeds
  • Dates
  • Gluten
  • Dairy
  • Oats
  • Barley
  • Soya
  • People who smoke or vape or have smoked or vaped in the last 2 years
  • People who consume more than 21 drinks a week or have a history of excess alcohol intake
  • People with comorbid conditions that may limit participation in the study, such as a history of an acute cardiovascular event, including coronary artery disease, previous myocardial infarction (heart attack), stroke, peripheral artery disease, diabetes mellitus, chronic kidney disease, metabolic syndrome, , cardiac arrhythmia, renal failure, cardiac failure, uncontrolled hypertension, cancer or major psychiatric or cognitive problems
  • People receiving drug treatment for lipid metabolisms (e.g., statins)
  • People with a history of long-term use of medicines known to influence glucose metabolism (e.g., ) or aspirin
  • People taking antihypertensive drugs
  • People who take antibiotics or bacterial agents (Probiotics) within 1 month
  • People who take vitamin/dietary supplements within 1 month
  • Pregnant women, women ready for pregnancy, and nursing mothers
  • cardiac arrhythmia
  • renal failure
  • heart failure ( II-IV)
  • diabetes mellitus
  • Malignant disease
  • People who have participated in a biomedical study within the past 3 months
  • Women who require hormone replacement therapy during the development of the protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    functional snacks then placebo snacks

    Daily consumption of 2 pouches of function snacks (50 g per pouch, rich in phytochemicals and fibres) for 28 days, then crossing over to the placebo snacks

    Dietary Supplement: Functional Snacks · Other: Placebo Snacks

  • Experimental
    placebo snacks then functional snacks

    Daily consumption of 2 pouches of placebo snacks (50 g per pouch, less in phytochemicals and fibres) for 28 days, then crossing over to the functional snacks

    Dietary Supplement: Functional Snacks · Other: Placebo Snacks

Interventions

  • Dietary supplementFunctional Snacks

    A type of phytochemical and fibre rich snack that created and produced by TulaCode called Cinnamon Granola Bark (50 g per pouch). The snack contains the following ingredients: Amaranth, coconut flakes, chia seeds, pumpkin seeds, sunflower seeds, pecans, brazil nuts, almonds, dates, banana, cold pressed extra virgin olive oil, 100% cocoa mass, cocoa butter, chicory root fibre, cinnamon, cloves, nutmeg, ginger, ground vanilla pod, natural Bourbon vanilla flavouring, salt

  • OtherPlacebo Snacks

    A type of calorie-matched commercially available chocolate snack, Mini Cornflake Cluster Bites (50 g per pouch). The snack contains the following ingredients: Milk chocolate (60%) (sugar, cocoa butter, cocoa mass, skimmed milk powder, milk fat, lactose (milk), emulsifier (soya lecithin)), corn flakes (40%) (maize, sugar, salt, barley malt extract, dextrose, niacin, iron, vitamin B6, riboflavin, vitamin B1, folic acid, vitamin B12)

06

What researchers measure

Primary outcomes

  1. Changes in menopause rating scale (MRS) of perimenopausal women

    To assess menopause-related symptoms of perimenopausal women, using the menopause rating scale (MRS). The scale consists in 11 items ranging from 0 (none) to 4 (very severe).

    Time frame: Baseline & 4 weeks

Secondary outcomes

  1. Changes in subjective (perceived) stress level of perimenopausal women

    The subjective stress level of perimenopausal women are assessed using the Perceived Stress Scale (PSS) questionnaire. The scale consists in 10 items rated on a 5-point Likert scale.

    Time frame: Baseline & 4 weeks

  2. Changes in affect in perimenopausal women

    To assess the affect of perimenopausal women, using the Positive and Negative Affect Schedule (PANAS-SF) questionnaire, consisting of 20 items rated from 1 (very slightly or not at all) to 5 (extremely).

    Time frame: Baseline & 4 weeks

  3. Changes in female sex hormone levels of perimenopausal women

    To assess the female sex hormone levels of perimenopausal women, measured several esterone levels in blood samples using the randox clinical biochemistry analyser.

    Time frame: Baseline & 4 weeks

  4. Changes in cognitive function of perimenopausal women

    To assess cognitive function of perimenopausal womenm using Cognitive Failures questionnaire (CFQ). The questionnaire consists of 25 questions rated on a 5-point Likert scale from 0 ("Never") to 4 ("Very often").

    Time frame: Baseline & 4 weeks

  5. Changes in mental health and wellbeing metabolites level of perimenopausal women

    To assess the metabolites related to mental health and wellbeing of perimenopausal women, measured a pack of metabolites/compounds including gut-brain axis metabolites, inflammatory markers, short-chain fatty acid, in plasma samples using Randox clinical biochemistry analyser and LC-MS.

    Time frame: Baseline & 4 weeks

  6. Habitual diet of perimenopausal women

    Habitual diet is assessed via the food frequency questionnaire (FFQ), items ranging from "never" to "multiple times a day"-they consumed specific food and beverage items from a predefined list

    Time frame: Baseline only

  7. Gut microbiome of perimenopausal women

    To investigate the role of the gut microbiome on the perimenopause symptoms. Gut microbiome diversity and composition will be analysed using 16s RNA sequencing technique as a pack.

    Time frame: Baseline & 4 weeks

  8. Changes in hormonal stress levels in perimenopausal women

    Stress measured as the cortisol level changes in saliva samples by LC-MS, including the cortisol levels at 0 min, 15 min, 30 min and 60 min after wakening and 12 pm and 8 pm on the day.

    Time frame: Baseline & 4 weeks

  9. Changes in mood in perimenopausal women

    To assess the overall changes in mood, using the Hospital Anxiety and Depression Scale (HADS), consist of 14 items rated on a 0-21 scale, with a higher score indicates a severe symptom.

    Time frame: Baseline & 4 weeks

  10. Changes in sleep quality in perimenopausal women

    Sleep quality changes measured using Pittsburgh Sleep Quality Index (PSQI) questionnaire, consist of 19 items rated on a 0-3 scale with higher scores indicating poorer sleep quality.

    Time frame: Weekly from baseline to 4 weeks

  11. Changes in physical activity level in perimenopausal women

    Changes in physical activity measured using the International Physical Activity questionnaire (IPAQ), producing a total activity score expressed in metabolic equivalent minutes per week (MET-min/week).

    Time frame: Weekly from baseline to 4 weeks

  12. Changes in quality of life in perimenopausal women

    Changes in quality of life measured using the World Health Organisation Quality of Life Assessment Instrument (EF-WHOQOL-100), a 100 item questionnaire with responses rated on a 1-5 Likert scale

    Time frame: Baseline & 4 weeks

  13. Changes in gastrointestinal symptoms of perimenopausal women

    Changes in the gastrointestinal function measured using Gastrointestinal Symptom Rating Scale (GSRS) questionnaire, consisting of 15 items rated from 1 (no discomfort) to 7 (very severe discomfort).

    Time frame: Weekly from baseline to 4 weeks

  14. Changes in weight of perimenopausal women

    Weight will be measured in kilograms using a body composition analyser (Tanita BC-418 MA)

    Time frame: Baseline & 4 weeks

  15. Height of perimenopausal women

    Height in centimeters will be measured using a stadiometer

    Time frame: Baseline

  16. Changes in BMI of perimenopausal women

    Changes in BMI will be measured by weighing participants using the body composition analyser (Tanita BC-418 MA) and calculating BMI from participant height and weight

    Time frame: Baseline & 4 weeks

  17. Changes in hip-waist circumference of perimenopausal women

    Hip and waist circumference will be measured in centimeters using a measuring tape

    Time frame: Baseline & 4 weeks

  18. Changes in blood pressure of perimenopausal women

    Blood pressure will be measured using an electric sphygmomanometer blood pressure monitor in millimeters of mercury (mmHg).

    Time frame: Baseline & 4 weeks

  19. Heart rate of perimenopausal women

    Heart rate will be measured in beats per minute using an electric sphygmomanometer blood pressure monitor

    Time frame: Baseline & 4 weeks

  20. Dietary polyphenol intake of perimenopausal women

    Polyphenol intake measured via the Food-Frequency Questionnaire - Polyphenol. Food items are rated from "Never" to "More than 6 times per day".

    Time frame: Baseline

  21. Weekly diet of perimenopausal women

    Weekly diet using Intake24, an online 24-hour dietary recall system that records all foods and drinks consumed during the previous day. It uses portion-size images and structured prompts to improve accuracy and reduce under-reporting.

    Time frame: Weekly from baseline to week 4

  22. Weekly diet of perimenopausal women

    Weekly diet will be measured using OPIS, a mobile application using artificial intelligence to estimate the nutrients and components of meals. Participants take a picture of their meals for 24 hours in the application and AI breaks down the make-up of the food.

    Time frame: Weekly from baseline to week 4

Other outcomes

  1. Plasma and Urinary metabolites of (poly)phenols of perimenopausal women

    In total more than 160 phenolic compounds and phase 2 metabolites will be measured in plasma and urine samples by LC-MS.

    Time frame: Baseline and 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 8 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 20, 2026
StartActual
Apr 24, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07599930
Collaborators
Tulā Code Ltd
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Apr 24, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 20, 2026

Study contacts

Ana Rodriguez-Mateos, PhD
Contact
ana.rodriguez-mateos@kcl.ac.uk
+44 (0)20 7848 4349 ext. 84349
Zicheng Zhang, PhD
Contact
swap@kcl.ac.uk
+44 (0)20 7848 0313 ext. 80313
Ana Rodriguez-Mateos, PhD
principal investigator · King's College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion